AOD-9604: The HGH Fat-Loss Fragment Research Summary

Category: Weight Management | Reading time: 9 min | Evidence level: Mixed (human Phase II/III + animal RCT)

---

AOD-9604 (Anti-Obesity Drug 9604) is a stabilized synthetic analogue of the C-terminal fragment of human growth hormone — specifically residues 177 to 191 of the 191-amino acid HGH sequence. It was engineered with a specific goal: retain HGH’s fat-mobilizing effects while eliminating the growth-promoting, insulin-antagonizing, and IGF-1-elevating effects that make full HGH problematic for metabolic applications.

Whether it succeeded is more nuanced than marketing materials suggest.

Disclaimer: AOD-9604 is not approved for human therapeutic use in any jurisdiction. This content is for educational and research purposes only. Not medical advice.

---

Background: Why Fragment HGH?

Full human growth hormone affects multiple systems simultaneously:

• Lipolysis: Breaks down stored fat (desired)
• IGF-1 elevation: Anabolic and growth-promoting (not desired for pure fat loss)
• Insulin antagonism: Raises blood glucose (problematic in metabolic syndrome)
• Cartilage and bone growth: Acromegalic risk with chronic supraphysiological doses

The C-terminal fragment (residues 176–191, slightly varying across the literature) was identified in the 1990s as primarily responsible for the lipolytic signaling, with substantially reduced growth hormone receptor activity. AOD-9604 is a tyrosine-modified version of this fragment designed for improved stability.

---

Mechanism of Action

AOD-9604’s proposed mechanism involves:

1. Beta-3 adrenergic receptor activation — The primary pathway. β3 receptors on adipocytes trigger cAMP signaling cascades that activate hormone-sensitive lipase (HSL), which breaks down triglycerides stored in fat cells.

2. Minimal GH receptor binding — Unlike full HGH, AOD-9604 has dramatically reduced affinity for the GH receptor, explaining the absent IGF-1 elevation and growth effects seen in studies.

3. Possible PPAR-γ interactions — Some animal research suggests metabolic gene expression effects beyond simple adrenergic signaling, though this remains less characterized.

What it does NOT do (per the research):

• Does not significantly elevate IGF-1
• Does not antagonize insulin signaling in humans at studied doses
• Does not appear to stimulate cellular proliferation

---

Human Clinical Trial History

AOD-9604 went through a genuine and unusually extensive human clinical trial program for a research peptide — a fact that makes the evidence base more interpretable than most compounds in this category.

Phase I: Safety and Pharmacokinetics

Established tolerability across dose ranges (25 mcg/kg to 400 mcg/kg), confirmed rapid absorption and clearance, documented the absence of IGF-1 elevation and insulin effects.

Phase IIa (METAOD 001)

12-week, double-blind, randomized, placebo-controlled trial in 300 obese subjects.
Results: AOD-9604 showed statistically significant fat loss versus placebo at specific dose levels (1 mg/day). Higher doses did not show proportionally greater results — a dose-response relationship that plateaued.

Phase IIb (METAOD 002)

24-week, multicenter, 500+ subjects. Results were more modest — statistically significant fat loss at the 1 mg dose was not consistently replicated across the larger trial. The study was considered inconclusive for the primary endpoint.

Phase III

A Phase III trial was initiated but the program was discontinued. The developer (Metabolic Pharmaceuticals, later acquired) cited the inadequate Phase IIb signal as insufficient to justify full Phase III investment.

FDA GRAS Status (2014): AOD-9604 was granted Generally Recognized As Safe status by the FDA for use as a food ingredient — a separate determination from therapeutic approval, but relevant to its safety profile characterization.

---

Animal Research

While human trial results were mixed, the animal research base is substantially more robust:

• Obese mouse models: Consistent, dose-dependent fat loss in ob/ob and diet-induced obesity models
• Osteoarthritis models: Unexpectedly, Australian research documented cartilage regenerative effects in animal models — a serendipitous finding that redirected some research interest toward joint applications
• No muscle wasting: Unlike caloric restriction, AOD-9604 reduced fat mass without lean mass loss in animal studies

The animal-to-human translation issue is real here: the same β3 adrenergic pathway that is prominent in rodent adipose tissue is less dominant in human adipocytes, which may partially explain the more modest human clinical results.

---

Current Research Context

The most active current research thread for AOD-9604 is intra-articular injection for osteoarthritis — notably divergent from the original fat loss focus. Paradigm Biopharmaceuticals (Australia) holds patents and has run Phase I/II trials for knee osteoarthritis using subcutaneous and intra-articular AOD-9604, showing anti-inflammatory and cartilage-protective effects.

This represents a genuine pivot in the evidence base: the compound’s most clinically promising application may not be the one it was designed for.

---

Protocol Notes for Research Contexts

Commonly studied doses: 300–500 mcg/day subcutaneous injection, or 500 mcg–1 mg oral
Oral bioavailability: Lower than injectable but documented; oral use is common in practice despite reduced expected efficacy
Cycle length: 12 weeks typical in trial contexts
Timing: Often administered in a fasted state in research protocols to align with endogenous fat-mobilization windows

---

What the Evidence Actually Supports

Honest assessment:

Claim	Evidence Status
Lipolytic activity in animals	✅ Robust rodent data
Fat loss in humans	⚠️ Modest Phase IIa signal; Phase IIb inconclusive
No IGF-1 elevation	✅ Consistently confirmed in human trials
No insulin antagonism	✅ Confirmed in human trials
Cartilage repair	⚠️ Animal data + Phase I/II for OA; not fully established
Better than caloric restriction	❌ No comparative RCT data

AOD-9604 is a case study in the gap between a compelling mechanism and real-world clinical outcomes. The Phase IIa signal was real but not robust enough to carry through Phase IIb. Researchers using it should calibrate expectations accordingly.

---

Related Guides

• Tesamorelin: FDA-Approved GHRH Analogue for Visceral Fat
• GLP-1 Peptides in Context: Semaglutide and Tirzepatide Research
• Weight Management Guides Overview

---

All content is for educational and research purposes only. Not medical advice or an endorsement of any specific product or protocol.